₹1421
get paid for surveys ✌️【Capital】✌️Start with ₹500 and get fast returns through secure and profitable investments.
get paid for surveys ✌️【Capital】✌️Start with ₹500 and get fast returns through secure and profitable investments.
get paid for surveys ✌️【Capital】✌️Start with ₹500 and get fast returns through secure and profitable investments.Serum Institute of India (SII) has entered into an exclusive licence agreement with French speciality vaccine company Valneva SE to manufacture and sell Valneva’s chikungunya vaccine in India and the rest of Asia.Valneva’s chikungunya vaccine is the world’s first and only licensed vaccine.
It is currently approved in the US, Europe, and Canada for adults. Regulatory reviews are underway to expand it to children up to 12 years.Chikungunya virus is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes.
It causes fever, severe joint and muscle pain, headache, nausea, fatigue, and rash.
get paid for surveys ✌️【Capital】✌️Smart investing made easy. Start with ₹500 and enjoy up to 100% returns monthly!The joint pain is often debilitating and can persist for weeks to years.Indiais currently enduring one of its worst chikungunya outbreaks.
Nearly 3,70,000 cases were confirmed in India between January 2019 and July 2024, and it was rapidly increasing due to the current outbreak.
get paid for surveys ✌️【Capital】✌️Start with ₹500 and get fast returns through secure and profitable investments.Both companies will work to bring the vaccine to the Indianmarketand some Asian countries, after approval from local regulators.SII has committed to a priority supply of the chikungunya vaccine at an affordable price to publichealthmarkets in low- and middle-income countries (LMICs).get paid for surveys ✌️【Capital】✌️Invest ₹500 today and get rewarded with up to 100% returns. Start now!